These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3602028)

  • 21. Alteration in dopaminergic and muscarinic cholinergic receptors after subchronic treatment with haloperidol in the developing rat brain.
    Kajiyama H; Nomura Y
    J Pharmacobiodyn; 1981 Feb; 4(2):85-90. PubMed ID: 7196947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia.
    Koller W; Curtin J; Fields J
    Neuropharmacology; 1984 Oct; 23(10):1191-4. PubMed ID: 6240609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic treatments with zotepine, thioridazine, and haloperidol affect apomorphine-elicited stereotypic behavior and striatal 3H-spiroperidol binding sites in the rat.
    Lai H; Carino MA; Horita A
    Psychopharmacology (Berl); 1981; 75(4):388-90. PubMed ID: 6122233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Definition of the in-vivo accumulation of [3H]spiperone in brain using haloperidol and sulpiride to determine functional dopamine receptor occupation.
    Chivers JK; Reavill C; Jenner P; Marsden CD
    J Pharm Pharmacol; 1988 Sep; 40(9):613-9. PubMed ID: 2907027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Eur J Pharmacol; 1980 May; 63(2-3):145-57. PubMed ID: 6103814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
    Schröder U; Schröder H; Augustin W; Sabel BA
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol releasing polymers.
    Köhler U; Schröder H; Augustin W; Sabel BA
    Neurosci Lett; 1994 Mar; 170(1):99-102. PubMed ID: 8041522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevation of circulating prolactin concentrations may not cause striatal dopamine receptor supersensitivity.
    Rupniak N; Hong M; Mansfield S; Fleminger S; Dyer R; Jenner P; Marsden CD
    Eur J Pharmacol; 1983 Sep; 93(3-4):195-200. PubMed ID: 6139285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic evaluation of dopaminergic receptor blockade by metoclopramide.
    Hassan MN; Reches A; Kuhn C; Higgins D; Fahn S
    Clin Neuropharmacol; 1986; 9(1):71-8. PubMed ID: 3829008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen inhibits the dopaminergic supersensitivity induced by neuroleptics.
    Fields JZ; Gordon JH
    Life Sci; 1982 Jan; 30(3):229-34. PubMed ID: 7200183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding.
    Pierce RC; Rowlett JK; Bardo MT; Rebec GV
    Neuroscience; 1991; 45(2):373-8. PubMed ID: 1762684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative analysis of [3H]spiroperidol binding to rat forebrain sections: plasticity of neostriatal dopamine receptors after nigrostriatal injury.
    Neve KA; Altar CA; Wong CA; Marshall JF
    Brain Res; 1984 Jun; 302(1):9-18. PubMed ID: 6428705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential alteration in striatal dopaminergic and cortical serotonergic receptors induced by repeated administration of haloperidol or centbutindole in rats.
    Gulati A; Srimal RC; Dhawan BN
    Pharmacology; 1988; 36(6):396-404. PubMed ID: 2901759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of pertussis toxin on D2-dopamine receptor in rat striatum: evidence for coupling of Ni regulatory protein with D2-receptor.
    Fujita N; Nakahiro M; Fukuchi I; Saito K; Yoshida H
    Brain Res; 1985 May; 333(2):231-6. PubMed ID: 3158374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol.
    Lynch MR
    Neuropsychobiology; 1990-1991; 24(2):102-8. PubMed ID: 2151972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined.
    Rastogi SK; Rastogi RB; Singhal RL; Lapierre YD
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(2-3):153-64. PubMed ID: 6137027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aging and the regulation of striatal dopaminergic mechanisms in mice.
    Randall PK; Severson JA; Finch CE
    J Pharmacol Exp Ther; 1981 Dec; 219(3):695-700. PubMed ID: 7197719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are the catecholestrogens involved in estrogen-induced striatal dopamine receptor supersensitivity?
    Ferretti C; Ghi P; Blengio M; Gaietta G; Barrera G; Genazzani E
    Eur J Pharmacol; 1989 Jul; 166(2):149-56. PubMed ID: 2551698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged inhibition of striatal dopamine receptor sites by isofloxythepin.
    Lau YS; Runice C
    Eur J Pharmacol; 1985 Oct; 116(1-2):25-31. PubMed ID: 2865162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent treatment with benztropine and haloperidol attenuates development of behavioral hypersensitivity but not dopamine receptor proliferation.
    Carvey PM; Hitri A; Goetz CG; Tanner CM; Klawans HL
    Life Sci; 1988; 42(22):2207-15. PubMed ID: 3374255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.